StockNews.AISignal intelligence
Company intelligence

ARTV

Artiva Biotherapeutics, Inc. Common Stock · NASDAQ

Price$4.01+1.26% · +$0.05
Market cap198.22MEquity value
P / E-1.2Trailing ratio
Volume868.51KLatest session
Market data

ARTV price chart

TradingView
Related signals
1 min delayed

Browse public ARTV signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ARTVOct 27, 2026-30.28% since signal

Artiva halts AlloNK program, assesses strategic options amid safety concerns

Artiva Biotherapeutics will discontinue AlloNK AB-101 development after longer-term data failed to meet durability thresholds, signaling a strategic shift away from autoimmune NK therapies. The company reported two Grade 5 safety events and plans a major workforce reduction while engaging Leerink Partners to explore strategic alternatives. Cash stands at about $319 million, supporting potential restructuring or a sale.

View signal analysis
Research

Company intelligence